Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Taps Genomics Collaborative for Two-Year Target Validation Project

NEW YORK, Sept. 22 (GenomeWeb News) - The Novartis Institutes for BioMedical Research (NIBRI) has selected Genomics Collaborative (GCI) as its partner for a two-year target validation project, GCI said today. 

NIBRI, the Cambridge, Mass.-based research arm institute of Novartis, will use GCI's Global Repostory database of human DNA, serum, and tissue samples in a research program to prioritize drug targets before entering clinical trials.

The non-exclusive research collaboration is for an initial two-year term, with the option to extend the program for two more years, GCI said. It will cover up to four therapeutic areas, beginning with type 2 diabetes.

GCI said that up to 100 genetic targets would be evaluated in 1,000 to 2,000 clinical samples for each therapeutic area.

Thomas Hughes, global head of NIBRI's diabetes disease area, said the project would help the company "find new and more effective ways to validate these targets and to establish the patient populations in which early drug candidates are most likely to succeed. This requires understanding variation in drug target genes and the impact of this variation on how compounds work in the human body before entering clinical trials."

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.